A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus

Clinical trial NCT01245166 · UNKNOWN

Trial details

NCT number: NCT01245166
Sponsor: Lotus Pharmaceutical
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

The Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 mg Thrice Daily Over 16 Weeks in Subjects With Type 2 Diabetes Mellitus.

Start date: 2010-11-01
Primary completion: 2011-06-01
Enrollment: 220

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.